Navigation Links
Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-CXCR4 Antibody, MDX-1338
Date:5/27/2009

-Clinical study planned for relapsed / refractory acute myelogenous leukemia-

PRINCETON, N.J., May 27 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today the allowance of an investigational new drug application (IND) filed with the U.S. Food & Drug Administration (FDA) for MDX-1338, for the treatment of patients with acute myelogenous leukemia (AML). MDX-1338 is a fully human antibody that targets CXCR4, a chemokine receptor found on the surface of many cancer cells, including certain leukemias, lymphomas and other cancers. Preclinical laboratory experiments have shown that MDX-1338 can block the growth of, and even directly kill, selected human tumor cells.

The Phase 1, open-label, multicenter, dose-escalation study of MDX-1338 as a monotherapy and in combination with chemotherapy is expected to enroll up to 34 patients with relapsed/ refractory AML. This trial is designed to establish and evaluate the safety, tolerability and maximum tolerated dose, as well as preliminary pharmacodynamics and efficacy of MDX-1338.

"We are pleased that MDX-1338 has progressed into the clinic, representing our eighth development candidate in oncology and further enhancing our focus on oncology/immunology therapeutic indications," said Howard H. Pien, Chairman and CEO of Medarex. "We believe that MDX-1338 could have potential activity in multiple cancers. Our first Phase 1 study will be conducted in AML and future studies are expected to target a variety of other leukemias and solid tumors and may involve monotherapy and combination therapy."

The American Cancer Society estimates that in 2008, approximately 13,290 patients in the United States will be diagnosed with AML.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology, product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. Over forty of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with the most advanced product candidates currently approved for commercial sale, the subject of regulatory applications for marketing authorization or in Phase 3 clinical trials. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com.

Medarex Statement on Cautionary Factors

Except for the historical information presented herein, the statements relating to MDX-1338 in this press release may constitute forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995, that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Medarex disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risks associated with product discovery and development of MDX-1338, as well as risks detailed from time to time in Medarex's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and its quarterly reports on Form 10-Q. There can be no assurance that such development efforts will succeed or that developed products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Copies of Medarex's public disclosure filings are available from its investor relations department.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis
2. Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer
3. Medarex Announces Enhanced Activity Data with Second Generation Anti-CD30 Antibody for Malignant Lymphoma
4. Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer
5. Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors
6. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
7. Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
8. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
9. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
10. Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
11. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... INDIANAPOLIS , Sept. 6, 2017 Eli ... today it will present new data for galcanezumab and ... Congress of the International Headache Society (IHC) taking place ... Lilly will highlight new, long-term data from ... two doses of galcanezumab (120 mg and 240 mg) ...
(Date:9/5/2017)... 18 months after its February 2016 launch, market access ... of three new senior people to its rapidly expanding ... and James Wright bring decades of specialist ... Tammy Wynne joins as Director, Value Communication, ... over ten years, experience in global market access consultancy ...
(Date:9/1/2017)... 2017  Bayer will present the latest research from across ... Oncology (ESMO) 2017 Congress, September 8-12 in Madrid, ... and clinical data on Bayer,s marketed portfolio and late-stage compounds ... "We value the opportunity ... research at ESMO," said Carsten Brunn , Head of ...
Breaking Medicine Technology:
(Date:9/26/2017)... ... 26, 2017 , ... Global healthcare company Novo Nordisk, renewed ... company’s commitment to the world’s first all-diabetes professional cycling team to a total ... partnered with the professional cycling team Team Type 1 to create Team Novo ...
(Date:9/26/2017)... ... September 26, 2017 , ... After a summer-long contest ... Campaign for Designated Drivers proudly announced the winners of the HEROtini Mocktail Challenge ... restaurants took on the challenge of competing in three categories: Best HEROtini Mocktail, ...
(Date:9/26/2017)... ... September 26, 2017 , ... ... expands services in Northern Colorado. Aspire Autism, A Division of Autism Learning Partners, ... Analysis (ABA) services. Aspire provides center based Autism services in Broomfield and will ...
(Date:9/26/2017)... ... September 26, 2017 , ... “Good Morning Sunshine!: Finding Strength and Comfort ... “Good Morning Sunshine!: Finding Strength and Comfort in God” is the creation of published ... Hays Sate University, who has worked at a local mental health center for over ...
(Date:9/26/2017)... ... , ... “The Tour Guide”: is the life story of the author and the exciting times ... Alexander Stark, is an adventure tour guide and the subject of the book. , ... confront fifteen shocked faces. I played it off as a part of the adventure tour, ...
Breaking Medicine News(10 mins):